Mirae Asset Global Etfs Holdings Ltd. Moon Lake Immunotherapeutics Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $41.5 Billion
- Q3 2024
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 13,590 shares of MLTX stock, worth $587,495. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,590
Previous 16,730
18.77%
Holding current value
$587,495
Previous $735,000
6.8%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding MLTX
# of Institutions
128Shares Held
58.5MCall Options Held
52.2KPut Options Held
38K-
Bvf Inc San Francisco, CA21.8MShares$940 Million34.86% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$367 Million30.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.98MShares$129 Million0.02% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.77MShares$120 Million2.1% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.32MShares$100 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.6B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...